The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant.
Jorge E. Cortes
Consultant or Advisory Role - Novartis
Alexander E. Perl
No relevant relationships to disclose
Hervé Dombret
No relevant relationships to disclose
Hartmut Dohner
Consultant or Advisory Role - Astellas Pharma
Honoraria - Ambit BioSciences
Bjoern Steffen
Other Remuneration - Ambit BioSciences
Philippe H. Rousselot
No relevant relationships to disclose
Giovanni Martinelli
No relevant relationships to disclose
Elihu Estey
No relevant relationships to disclose
Neil P. Shah
No relevant relationships to disclose
Alan K. Burnett
Consultant or Advisory Role - Ambit BioSciences
Guy Gammon
Employment or Leadership Position - Ambit BioSciences
Stock Ownership - Ambit BioSciences
Denise Trone
Employment or Leadership Position - Ambit BioSciences
Mark J. Levis
Consultant or Advisory Role - Astellas Pharma